Myeloma breakthrough? study tests if patients can ditch lifelong drugs
NCT ID NCT05866757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with multiple myeloma who have achieved a very deep remission (called MRD-negative) can stop their maintenance therapy without the cancer coming back quickly. It involves 70 adults who have been on maintenance therapy for at least two years. Researchers will check their bone marrow after 12 and 24 months to see how many remain cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cork University Hospital
RECRUITINGCork, Ireland, Ireland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?